New chemotherapy combinations for advanced bladder cancer.
Transitional cell carcinoma of the urothelium is considered a chemosensitive malignancy. Until recently, the methotrexate, vinblastine, doxorubicin and cisplatin combination has been considered the standard for treating this disease. The development of new chemotherapeutic agents such as gemcitabine and the taxanes has opened up promising new perspectives in the treatment of this disease. However, the preliminary phase II data must be confirmed in adequately conducted phase III trials.
Bellmunt
J
J
Medical Oncology Service, General University Vall d'Hebron Hospital, Barcelona, Spain. bellmunt@hg.vhebron.es
Albiol
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D002945:Cisplatin; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate; D009362:Neoplasm Metastasis; D010984:Platinum / Q000008:administration & dosage; D011379:Prognosis; D012720:Severity of Illness Index; D016019:Survival Analysis; D043823:Taxoids; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D014747:Vinblastine; D000093542:Gemcitabine
D001952:Bridged-Ring Compounds; D004338:Drug Combinations; D043823:Taxoids; D003841:Deoxycytidine; C080625:taxane; D010984:Platinum; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate; D000093542:Gemcitabine